CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The research, taken from the CLARITY study and published in GUT, found that 865 people given the Pfizer/BioNTech or the Oxford/AZ COVID-19 vaccine and treated with infliximab (Remicade) had significantly lower concentrations of antibodies when compared to 428 people on an alternative treatment, vedolizumab (Entyvio). Infliximab is prescribed to around two million people worldwide.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
